Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
6 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
8-K
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
22 Feb 24
8-K
Entry into a Material Definitive Agreement
18 Jan 24
8-K
Other Events
8 Jan 24
8-K
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
2 Nov 23
8-K
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
25 Sep 23
8-K
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
3 Aug 23
8-K
Regulation FD Disclosure
17 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
6 Mar 24
424B5
Prospectus supplement for primary offering
4 Mar 24
S-8
Registration of securities for employees
5 Jan 24
S-3ASR
Automatic shelf registration
2 Nov 23
S-3ASR
Automatic shelf registration
26 Jul 23
S-8
Registration of securities for employees
4 May 23
S-3ASR
Automatic shelf registration
4 May 23
424B5
Prospectus supplement for primary offering
9 Mar 23
424B5
Prospectus supplement for primary offering
6 Mar 23
S-8
Registration of securities for employees
6 Feb 23
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEF 14A
Definitive proxy
8 Nov 21
PRE 14A
Preliminary proxy
29 Oct 21
DEF 14A
Definitive proxy
30 Apr 21
DEFM14A
Proxy related to merger
15 Dec 20
Other
CT ORDER
Confidential treatment order
18 Jul 23
EFFECT
Notice of effectiveness
16 Dec 20
CORRESP
Correspondence with SEC
11 Dec 20
UPLOAD
Letter from SEC
13 Nov 20
CORRESP
Correspondence with SEC
6 Nov 20
SEC STAFF
SEC staff action: Order
27 Feb 20
SEC STAFF
SEC staff action: Order
7 Feb 20
CERT
Certification of approval for exchange listing
27 Jun 19
EFFECT
Notice of effectiveness
27 Jun 19
CORRESP
Correspondence with SEC
25 Jun 19
Ownership
4
Neil Kumar
14 Mar 24
4
BRIAN C STEPHENSON
14 Mar 24
4
Randal W. Scott
5 Mar 24
4
BRIAN C STEPHENSON
21 Feb 24
4
CHARLES J HOMCY
21 Feb 24
4
Neil Kumar
21 Feb 24
4
Hannah Valantine
20 Feb 24
SC 13G/A
Kumar Neil
16 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24